PMID- 22323913
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 2092-9900 (Electronic)
IS  - 1738-6756 (Print)
IS  - 1738-6756 (Linking)
VI  - 14
IP  - 4
DP  - 2011 Dec
TI  - Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ 
      Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.
PG  - 276-82
LID - 10.4048/jbc.2011.14.4.276 [doi]
AB  - PURPOSE: Valid determination of HER2 status is a prerequisite to establish an 
      adequate treatment strategy for breast cancer patients, regardless of the disease 
      stage. The goal of this study was to examine the feasibility of the newly 
      developed silver-enhanced in situ hybridization (SISH) technique as an 
      alternative to fluorescence in situ hybridization (FISH) for HER2 assay in 
      primary invasive breast cancer. METHODS: FISH and SISH for HER2 amplification 
      were performed using tissue microarray. Both methods were used in 257 consecutive 
      primary breast cancers. RESULTS: HER2 amplification was observed in 62 (23.1%) of 
      a total of 257 breast cancers based on SISH. Of the 257 breast cancers measured 
      using both methods, the results of the two methods were consistent in 248 
      (concordance, 96.5%; kappa=0.903). When we compared HER2 amplification in the 
      primary tumor with the metastatic lymph nodes of the same patients, HER2 
      amplification was observed in nine cases (14.0%) out of 64 cases in which HER2 
      was not amplified in the primary tumors. In contrast, HER2 status was completely 
      preserved in metastatic lymph nodes showing HER2 amplification in the primary 
      tumor. CONCLUSION: These results indicate that SISH can be a feasible alternative 
      to FISH in the clinical setting. In node-positive breast cancer, confirmation of 
      the HER2 status of the metastatic lymph nodes appears to be mandatory, regardless 
      of the HER2 status of the primary tumors.
FAU - Park, Kyeongmee
AU  - Park K
AD  - Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, Korea.
FAU - Han, Sehwan
AU  - Han S
FAU - Kim, Jung-Yeon
AU  - Kim JY
FAU - Kim, Hyun-Jung
AU  - Kim HJ
FAU - Kwon, Ji Eun
AU  - Kwon JE
FAU - Gwak, Geumhee
AU  - Gwak G
LA  - eng
PT  - Journal Article
DEP - 20111227
PL  - Korea (South)
TA  - J Breast Cancer
JT  - Journal of breast cancer
JID - 101314183
PMC - PMC3268923
OTO - NOTNLM
OT  - Breast neoplasms
OT  - HER2
OT  - In situ hybridization
COIS- The authors declare that they have no competing interests.
EDAT- 2012/02/11 06:00
MHDA- 2012/02/11 06:01
PMCR- 2011/12/01
CRDT- 2012/02/11 06:00
PHST- 2011/06/30 00:00 [received]
PHST- 2011/10/31 00:00 [accepted]
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2012/02/11 06:01 [medline]
PHST- 2011/12/01 00:00 [pmc-release]
AID - 10.4048/jbc.2011.14.4.276 [doi]
PST - ppublish
SO  - J Breast Cancer. 2011 Dec;14(4):276-82. doi: 10.4048/jbc.2011.14.4.276. Epub 2011 
      Dec 27.